StockData
Clene Inc. logo

Clene Inc. (CLNN) stock

CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$3.42+0.20 (+6.21%)

Close on Nov 18, 2026Market cap $43.94MP/E –Yield –

Clene operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Clene's operating income for the twelve months ending Jun 30, 2026 was -$20.55M. For fiscal 2025 it was -$23.08M. The highest annual figure on record is -$16.33M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.08M–
FY2024Dec 31, 2024-$33.09M–
FY2023Dec 31, 2023-$40.54M–
FY2022Dec 31, 2022-$48.41M–
FY2021Dec 31, 2021-$49.98M–
FY2020Dec 31, 2020-$20.21M–
FY2019Dec 31, 2019-$16.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.35M–
Q1 FY2026Mar 31, 2026-$2.06M–
Q4 FY2025Dec 31, 2025-$7.50M–
Q3 FY2025Sep 30, 2025-$5.65M–
Q2 FY2025Jun 30, 2025-$5.86M–
Q1 FY2025Mar 31, 2025-$4.08M–
Q4 FY2024Dec 31, 2024-$8.66M–
Q3 FY2024Sep 30, 2024-$7.82M–
Q2 FY2024Jun 30, 2024-$7.39M–
Q1 FY2024Mar 31, 2024-$9.23M–
Q4 FY2023Dec 31, 2023-$9.93M–
Q3 FY2023Sep 30, 2023-$9.54M–
Q2 FY2023Jun 30, 2023-$10.34M–
Q1 FY2023Mar 31, 2023-$10.73M–
Q2 FY2022Jun 30, 2022-$13.60M–
Q1 FY2022Mar 31, 2022-$13.34M–
Q4 FY2021Dec 31, 2021-$14.06M–
Q3 FY2021Sep 30, 2021-$10.45M–
Q2 FY2021Jun 30, 2021-$13.78M–
Q1 FY2021Mar 31, 2021-$11.70M–
Q4 FY2020Dec 31, 2020-$5.96M–
Q3 FY2020Sep 30, 2020-$5.69M–
Q2 FY2020Jun 30, 2020-$4.56M–
Q1 FY2020Mar 31, 2020-$4.00M–

More Clene figures

See a number that looks wrong?